{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:26:26Z","timestamp":1787955986269,"version":"build-2784847793"},"reference-count":24,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2022.2532","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T12:16:03Z","timestamp":1647605763000},"source":"Crossref","is-referenced-by-count":6,"title":["Mediastinal and hilar sarcoid\u2011like reaction in a patient treated with dabrafenib and trametinib for metastatic melanoma: A case report and review of the literature"],"prefix":"10.3892","volume":"16","author":[{"given":"Vanessa-Meletia","family":"Bala","sequence":"first","affiliation":[{"name":"2nd Department of Medical Oncology, General Oncology Hospital of Kifissia \u2018Agioi Anargyroi\u2019, Athens 145 64, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mitsogianni","sequence":"additional","affiliation":[{"name":"2nd Department of Medical Oncology, General Oncology Hospital of Kifissia \u2018Agioi Anargyroi\u2019, Athens 145 64, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Laschos","sequence":"additional","affiliation":[{"name":"2nd Department of Medical Oncology, General Oncology Hospital of Kifissia \u2018Agioi Anargyroi\u2019, Athens 145 64, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Pliakou","sequence":"additional","affiliation":[{"name":"2nd Department of Medical Oncology, General Oncology Hospital of Kifissia \u2018Agioi Anargyroi\u2019, Athens 145 64, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Lazaridi","sequence":"additional","affiliation":[{"name":"2nd Department of Medical Oncology, General Oncology Hospital of Kifissia \u2018Agioi Anargyroi\u2019, Athens 145 64, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra-Ioanna","family":"Lampropoulou","sequence":"additional","affiliation":[{"name":"2nd Department of Medical Oncology, General Oncology Hospital of Kifissia \u2018Agioi Anargyroi\u2019, Athens 145 64, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Aravantinos","sequence":"additional","affiliation":[{"name":"2nd Department of Medical Oncology, General Oncology Hospital of Kifissia \u2018Agioi Anargyroi\u2019, Athens 145 64, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"key20220428133215_b1-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"key20220428133215_b2-MCO-16-5-02532","first-page":"S13","article-title":"Your patient with melanoma: Staging, prognosis, and treatment","volume":"23 (Suppl 8)","author":"Rubin","year":"2009","journal-title":"Oncology (Williston Park)"},{"key":"key20220428133215_b3-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann Oncol"},{"key":"key20220428133215_b4-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.critrevonc.2013.01.003","article-title":"Targeting BRAF in melanoma: Biological and clinical challenges","volume":"87","author":"Mandal\u00e0","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"594118","key":"key20220428133215_b5-MCO-16-5-02532","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.594118","article-title":"Sarcoidosis and cancer: A complex relationship","volume":"7","author":"El Jammal","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"key20220428133215_b6-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000213245","article-title":"Sarcoidosis and melanoma: A referral center study of 1,199 cases","volume":"219","author":"Seve","year":"2009","journal-title":"Dermatology"},{"key":"key20220428133215_b7-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/joim.12991","article-title":"Drug-induced sarcoidosis: An overview of the WHO pharmacovigilance database","volume":"288","author":"Cohen Aubart","year":"2020","journal-title":"J Intern Med"},{"key":"key20220428133215_b8-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-like reactions induced by checkpoint inhibitors","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"102587","key":"key20220428133215_b9-MCO-16-5-02532","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102587","article-title":"Sarcoidosis related to checkpoint and BRAF\/MEK inhibitors in melanoma","volume":"19","author":"Rubio-Rivas","year":"2020","journal-title":"Autoimmun Rev"},{"key":"key20220428133215_b10-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/CMR.0000000000000437","article-title":"Sarcoid-like reactions in patients receiving modern melanoma treatment","volume":"28","author":"Dimitriou","year":"2018","journal-title":"Melanoma Res"},{"key":"key20220428133215_b11-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.4049\/jimmunol.1302616","article-title":"Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment","volume":"192","author":"Wilmott","year":"2014","journal-title":"J Immunol"},{"key":"key20220428133215_b12-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/bjd.12279","article-title":"Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: A report of two cases","volume":"169","author":"Green","year":"2013","journal-title":"Br J Dermatol"},{"key":"key20220428133215_b13-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1001\/jamadermatol.2013.7919","article-title":"Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma","volume":"150","author":"Park","year":"2014","journal-title":"JAMA Dermatol"},{"key":"key20220428133215_b14-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/CMR.0000000000000186","article-title":"Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib","volume":"25","author":"Jansen","year":"2015","journal-title":"Melanoma Res"},{"key":"key20220428133215_b15-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1111\/jdv.14467","article-title":"Acute heart failure as a result of granulomatous myocarditis: Case report on a patient with metastatic melanoma treated with dabrafenib and trametinib","volume":"32","author":"Winkler","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20220428133215_b16-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.oftal.2018.01.008","article-title":"Uveitis and serous retinal detachment secondary to systemic dabrafenib and trametinib","volume":"93","author":"Rueda-Rueda","year":"2018","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"key":"key20220428133215_b17-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jdcr.2018.05.011","article-title":"Subclinical granulomas in benign skin lesions heralding the onset of BRAF and MEK inhibitor-associated granulomatous dermatitis in a patient with metastatic melanoma","volume":"4","author":"Korman","year":"2018","journal-title":"JAAD Case Rep"},{"key":"key20220428133215_b18-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000499959","article-title":"Granulomatous reactions from tattoos following BRAF inhibitor therapy","volume":"11","author":"Giet","year":"2019","journal-title":"Case Rep Dermatol"},{"key":"key20220428133215_b19-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/CMR.0000000000000649","article-title":"Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: A monocentric retrospective study","volume":"30","author":"Huynh","year":"2020","journal-title":"Melanoma Res"},{"issue":"579523","key":"key20220428133215_b20-MCO-16-5-02532","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.579523","article-title":"Case report: Immune-related toxicity during adjuvant treatment with BRAF plus MEK inhibitors in a melanoma patient","volume":"11","author":"Boutros","year":"2020","journal-title":"Front Immunol"},{"key":"key20220428133215_b21-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/bjd.12268","article-title":"Sarcoidosis associated with vemurafenib","volume":"169","author":"Adam","year":"2013","journal-title":"Br J Dermatol"},{"key":"key20220428133215_b22-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/DAD.0000000000001276","article-title":"BRAF inhibitor-associated granulomatous dermatitis: A report of 3 cases","volume":"41","author":"Hui Ong","year":"2019","journal-title":"Am J Dermatopathol"},{"key":"key20220428133215_b23-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1684\/ejd.2019.3640","article-title":"Atypical systemic sarcoid-like granulomatosis in two patients treated with BRAF and MEK inhibitors","volume":"29","author":"Assan","year":"2019","journal-title":"Eur J Dermatol"},{"key":"key20220428133215_b24-MCO-16-5-02532","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1159\/000439400","article-title":"Sarcoidosis in patients treated with vemurafenib for metastatic melanoma: A paradoxical autoimmune activation","volume":"231","author":"Lheure","year":"2015","journal-title":"Dermatology"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T10:33:07Z","timestamp":1651141987000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2022.2532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3,18]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2022.2532","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"article-number":"99"}}